Jennifer P Collins1,2, Angela P Campbell3, Kyle Openo2, Monica M Farley2,4, Charisse Nitura Cummings3, Mary Hill5, William Schaffner6, Mary Lou Lindegren6, Ann Thomas7, Laurie Billing8, Nancy Bennett9, Nancy Spina10, Marisa Bargsten11, Ruth Lynfield12, Seth Eckel13, Patricia Ryan14, Kimberly Yousey-Hindes15, Rachel Herlihy16, Pam Daily Kirley17, Shikha Garg3, Evan J Anderson1,2,4. 1. Emory University School of Medicine, Department of Pediatrics, Atlanta, Georgia. 2. Emerging Infections Program, Atlanta VA Medical Center, Atlanta, Georgia. 3. Influenza Division, US Centers for Disease Control and Prevention, Atlanta, Georgia. 4. Emory University School of Medicine, Department of Medicine, Atlanta, Georgia. 5. Salt Lake Valley Health Department, Salt Lake City, Utah. 6. Vanderbilt University School of Medicine, Nashville, Tennessee. 7. Oregon Public Health Division, Portland. 8. Ohio Department of Health, Columbus. 9. University of Rochester Medical Center, New York. 10. New York State Department of Health, Albany. 11. New Mexico Department of Health, Santa Fe. 12. Minnesota Department of Health, St Paul. 13. Michigan Department of Health and Human Services, Lansing. 14. Maryland Department of Health and Mental Hygiene, Baltimore. 15. Connecticut Emerging Infections Program, Yale School of Public Health, New Haven. 16. Colorado Department of Public Health and Environment, Denver. 17. California Emerging Infections Program, Oakland.
Abstract
BACKGROUND: Hospitalized immunocompromised (IC) adults with influenza may have worse outcomes than hospitalized non-IC adults. METHODS: We identified adults hospitalized with laboratory-confirmed influenza during 2011-2015 seasons through CDC's Influenza Hospitalization Surveillance Network. IC patients had human immunodefiency virus (HIV)/AIDS, cancer, stem cell or organ transplantation, nonsteroid immunosuppressive therapy, immunoglobulin deficiency, asplenia, and/or other rare conditions. We compared demographic and clinical characteristics of IC and non-IC adults using descriptive statistics. Multivariable logistic regression and Cox proportional hazards models controlled for confounding by patient demographic characteristics, pre-existing medical conditions, influenza vaccination, and other factors. RESULTS: Among 35 348 adults, 3633 (10%) were IC; cancer (44%), nonsteroid immunosuppressive therapy (44%), and HIV (18%) were most common. IC patients were more likely than non-IC patients to have received influenza vaccination (53% vs 46%; P < .001), and ~85% of both groups received antivirals. In multivariable analysis, IC adults had higher mortality (adjusted odds ratio [aOR], 1.46; 95% confidence interval [CI], 1.20-1.76). Intensive care was more likely among IC patients 65-79 years (aOR, 1.25; 95% CI, 1.06-1.48) and those >80 years (aOR, 1.35; 95% CI, 1.06-1.73) compared with non-IC patients in those age groups. IC patients were hospitalized longer (adjusted hazard ratio of discharge, 0.86; 95% CI, .83-.88) and more likely to require mechanical ventilation (aOR, 1.19; 95% CI, 1.05-1.36). CONCLUSIONS: Substantial morbidity and mortality occurred among IC adults hospitalized with influenza. Influenza vaccination and antiviral administration could be increased in both IC and non-IC adults.
BACKGROUND: Hospitalized immunocompromised (IC) adults with influenza may have worse outcomes than hospitalized non-IC adults. METHODS: We identified adults hospitalized with laboratory-confirmed influenza during 2011-2015 seasons through CDC's Influenza Hospitalization Surveillance Network. IC patients had human immunodefiency virus (HIV)/AIDS, cancer, stem cell or organ transplantation, nonsteroid immunosuppressive therapy, immunoglobulin deficiency, asplenia, and/or other rare conditions. We compared demographic and clinical characteristics of IC and non-IC adults using descriptive statistics. Multivariable logistic regression and Cox proportional hazards models controlled for confounding by patient demographic characteristics, pre-existing medical conditions, influenza vaccination, and other factors. RESULTS: Among 35 348 adults, 3633 (10%) were IC; cancer (44%), nonsteroid immunosuppressive therapy (44%), and HIV (18%) were most common. IC patients were more likely than non-IC patients to have received influenza vaccination (53% vs 46%; P < .001), and ~85% of both groups received antivirals. In multivariable analysis, IC adults had higher mortality (adjusted odds ratio [aOR], 1.46; 95% confidence interval [CI], 1.20-1.76). Intensive care was more likely among IC patients 65-79 years (aOR, 1.25; 95% CI, 1.06-1.48) and those >80 years (aOR, 1.35; 95% CI, 1.06-1.73) compared with non-IC patients in those age groups. IC patients were hospitalized longer (adjusted hazard ratio of discharge, 0.86; 95% CI, .83-.88) and more likely to require mechanical ventilation (aOR, 1.19; 95% CI, 1.05-1.36). CONCLUSIONS: Substantial morbidity and mortality occurred among IC adults hospitalized with influenza. Influenza vaccination and antiviral administration could be increased in both IC and non-IC adults.
Authors: Carmen S Arriola; Evan J Anderson; Joan Baumbach; Nancy Bennett; Susan Bohm; Mary Hill; Mary Lou Lindegren; Krista Lung; James Meek; Elizabeth Mermel; Lisa Miller; Maya L Monroe; Craig Morin; Oluwakemi Oni; Arthur Reingold; William Schaffner; Ann Thomas; Shelley M Zansky; Lyn Finelli; Sandra S Chaves Journal: J Infect Dis Date: 2015-03-27 Impact factor: 5.226
Authors: Carlos G Grijalva; Yuwei Zhu; Derek J Williams; Wesley H Self; Krow Ampofo; Andrew T Pavia; Chris R Stockmann; Jonathan McCullers; Sandra R Arnold; Richard G Wunderink; Evan J Anderson; Stephen Lindstrom; Alicia M Fry; Ivo M Foppa; Lyn Finelli; Anna M Bramley; Seema Jain; Marie R Griffin; Kathryn M Edwards Journal: JAMA Date: 2015-10-13 Impact factor: 56.272
Authors: Carmen Arriola; Shikha Garg; Evan J Anderson; Patrician A Ryan; Andrea George; Shelley M Zansky; Nancy Bennett; Arthur Reingold; Marisa Bargsten; Lisa Miller; Kimberly Yousey-Hindes; Lilith Tatham; Susan R Bohm; Ruth Lynfield; Ann Thomas; Mary Lou Lindegren; William Schaffner; Alicia M Fry; Sandra S Chaves Journal: Clin Infect Dis Date: 2017-10-15 Impact factor: 9.079
Authors: Evan J Anderson; Michael A Daugherty; Larry K Pickering; Walter A Orenstein; Ram Yogev Journal: Clin Infect Dis Date: 2018-07-18 Impact factor: 9.079
Authors: Melissa A Rolfes; Ivo M Foppa; Shikha Garg; Brendan Flannery; Lynnette Brammer; James A Singleton; Erin Burns; Daniel Jernigan; Sonja J Olsen; Joseph Bresee; Carrie Reed Journal: Influenza Other Respir Viruses Date: 2018-02-14 Impact factor: 4.380
Authors: Inci Yildirim; Carol M Kao; Ashley Tippett; Piyarat Suntarattiwong; Mohamed Munye; Jumi Yi; Mohnd Elmontser; Elizabeth Quincer; Chris Focht; Nora Watson; Hande Bilen; Julia M Baker; Ben Lopman; Elena Hogenesch; Christina A Rostad; Evan J Anderson Journal: Clin Infect Dis Date: 2021-11-16 Impact factor: 20.999
Authors: Daniel Owusu; Melissa A Rolfes; Carmen S Arriola; Pam Daily Kirley; Nisha B Alden; James Meek; Evan J Anderson; Maya L Monroe; Sue Kim; Ruth Lynfield; Kathy Angeles; Nancy Spina; Christina B Felsen; Laurie Billing; Ann Thomas; H Keipp Talbot; William Schaffner; Ryan Chatelain; Carrie Reed; Shikha Garg Journal: Open Forum Infect Dis Date: 2022-03-16 Impact factor: 4.423
Authors: Elie Azoulay; Lene Russell; Andry Van de Louw; Victoria Metaxa; Philippe Bauer; Pedro Povoa; José Garnacho Montero; Ignacio Martin Loeches; Sangeeta Mehta; Kathryn Puxty; Peter Schellongowski; Jordi Rello; Djamel Mokart; Virginie Lemiale; Adrien Mirouse Journal: Intensive Care Med Date: 2020-02-07 Impact factor: 17.440
Authors: Kailey Hughes; Donald B Middleton; Mary Patricia Nowalk; Goundappa K Balasubramani; Emily T Martin; Manjusha Gaglani; H Keipp Talbot; Manish M Patel; Jill M Ferdinands; Richard K Zimmerman; Fernanda P Silveira Journal: Clin Infect Dis Date: 2021-12-06 Impact factor: 9.079
Authors: Janet E McElhaney; Chris P Verschoor; Melissa K Andrew; Laura Haynes; George A Kuchel; Graham Pawelec Journal: Immun Ageing Date: 2020-05-07 Impact factor: 6.400